bullish

Shroom Shmooz - How Valid Are ICER’s Concerns About MAPS’ MDMA- AT Trials?

365 Views11 May 2024 06:33
Issuer-paid
In March, the Institute fo  Clinical and Economic Review (ICER) published its draft evidence report on MAPS’ (aka Lykos Therapeutics) Phase III clinical trials.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 16-minute read)
Discussions
(Paid Plans Only)
Logo
Water Tower Research
Research from Water Tower Research
Water Tower Research
Equity Bottom-UpThematic (Sector/Industry)
  • Shroom Shmooz - How Valid Are ICER’s Concerns About MAPS’ MDMA- AT Trials?
    11 May 2024
x